HOME > Chiesi Press Release > Chiesi Group and Bayer announce co-promotion agreement for respiratory treatments Clenil® and Foster® in China

Chiesi Group and Bayer announce co-promotion agreement for respiratory treatments Clenil® and Foster® in China

Shanghai, China, July 13th, 2020 – Chiesi Farmaceutici S.p.A, the international research-focused healthcare Group (Chiesi Group), and Bayer today announced that they have entered into a co-promotion agreement for Clenil® and Foster® in China, two products of Chiesi Group’s established portfolio in the respiratory therapeutic area. The partnership aims to integrate commercial expertise and resources of both companies in China to improve access to treatment options for Chinese patients suffering from respiratory diseases.


Chronic respiratory diseases are among the major noncommunicable diseases in China. Two of the most common are asthma and chronic obstructive pulmonary disease (COPD), both of which lead to high unmet medical needs among the Chinese population. A national study shows that the country is estimated to have more than 45.7 million adults with asthma, only around 5.6 percent of whom have received proper treatment.1 In addition, around 100 million Chinese people are suffering from COPD, accounting for 8.6 percent of the country’s adult population.2


“As a global leader with over 85 years of track record and expertise in treating respiratory diseases, Chiesi is fully committed to the care and improvement of patients’ quality of life,” said Davide Dalle Fusine, General Manager, Chiesi Pharmaceutical (Shanghai) Co. Ltd. “Through this new partnership with Bayer, we would further expand the access to benefit more patients in China. We are excited to join forces with Bayer and to contribute more in the management of chronic respiratory diseases.”


Chronic respiratory diseases, together with cardiovascular diseases and diabetes, are prioritized by the Chinese central government in its Healthy China Action Plan in efforts to address major health challenges caused by the prevalence of chronic diseases.


“In support of the Healthy China strategy, Bayer is dedicated to fulfilling its commitment to advancing chronic disease management and providing comprehensive solutions by leveraging our expertise in healthcare complemented by external know-how through partnerships,” said Wei Jiang, Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC and President of Bayer Group Greater China. “We are pleased that the partnership with Chiesi expands our efforts to a broader spectrum of respiratory diseases, which enables us to help more patients suffering from respiratory disease to benefit from Chiesi’s established treatments. Collaborating with outstanding partners like Chiesi is a cornerstone of Bayer's strategy to transform innovation into meaningful solutions for patients in China.”


In China, Clenil (beclometasone) is approved by the National Medical Products Administration for treating asthma and symptom relief of bronchus obstruction in adults and children. Foster (beclomethasone/formoterol) is approved in China for the regular treatment of asthma in adult patients. Foster utilizes Chiesi's proprietary Modulite® technology, which creates an extra fine solution enabling more even distribution in the lung starting from a lower dose of corticosteroid.


Under the terms of the agreement, Chiesi and Bayer will collaborate to promote Clenil and Foster in China. 


The Pharmaceuticals Business Development & Licensing team of Bayer facilitated this collaboration.



About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.


Chiesi Pharmaceutical Shanghai Communications

Tel No.: (86)21-5258-8899*881

Email: china.communications@chiesi.com